AK119
AK119 is a pharmaceutical drug with 7 clinical trials. Currently 2 active trials ongoing. Historical success rate of 60.0%.
Success Metrics
Based on 3 completed trials
Phase Distribution
Phase Distribution
7
Early Stage
0
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 1Trial Status & Enrollment
60.0%
3 of 5 finished
40.0%
2 ended early
2
trials recruiting
7
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
Clinical Trials (7)
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects
A Study of AK119 (Anti-CD73) in Combination With AK104 in Subjects With Advanced Solid Tumors
Study of AK119 Combined With AK104 in Patients With Advanced Solid Tumors
Study of AK119 in Subjects With Advanced Solid Tumors
All 7 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 7